

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Pancreas: Head

C25.0

C25.0 Head of pancreas

Note: For tumors of the islet cells, determine which subsite of the pancreas is involved and use that primary site code and the corresponding Collaborative Stage scheme. If the subsite cannot be determined, use the general code for Islets of Langerhans, C25.4, and use the Collaborative Stage scheme for Pancreas, Other and Unspecified.

CS Tumor Size	CS Site-Specific Factor 1 CA 19-9 Lab Value	The following tables are available at the collaborative staging website: Histology Inclusion Table AJCC 7th ed. Histology Exclusion Table AJCC 6th ed. AJCC TNM 7 Stage AJCC TNM 6 Stage Summary Stage Extension Size Table
CS Extension	CS Site-Specific Factor 2 Serum Chromogranin A (CgA) Lab Value	
CS Tumor Size/Ext Eval	CS Site-Specific Factor 3 Mitotic Count	
CS Lymph Nodes	CS Site-Specific Factor 4	
CS Lymph Nodes Eval	CS Site-Specific Factor 5	
Reg LN Pos	CS Site-Specific Factor 6	
Reg LN Exam	CS Site-Specific Factor 7	
CS Mets at DX	CS Site-Specific Factor 8	
CS Mets Eval	CS Site-Specific Factor 9	
	CS Site-Specific Factor 10	
	CS Site-Specific Factor 11	
	CS Site-Specific Factor 12	
	CS Site-Specific Factor 13	
	CS Site-Specific Factor 14	
	CS Site-Specific Factor 15	
	CS Site-Specific Factor 16	
	CS Site-Specific Factor 17	
	CS Site-Specific Factor 18	
	CS Site-Specific Factor 19	
	CS Site-Specific Factor 20	
	CS Site-Specific Factor 21	
	CS Site-Specific Factor 22	
	CS Site-Specific Factor 23	
	CS Site-Specific Factor 24	
	CS Site-Specific Factor 25	

Pancreas: Head

CS Tumor Size (Revised: 06/08/2009)

Note: Code the specific tumor size as documented in the medical record. If the ONLY information regarding tumor size is the clinician's statement of the "T" category, assign code 992 (T1, NOS) or 993 (T2, NOS). (Refer to the CS Extension table for instructions on coding extension).

Code	Description
000	No mass/tumor found
001-988	001 - 988 millimeters (code exact size in millimeters)
989	989 millimeters or larger
990	Microscopic focus or foci only, no size of focus given
991	Described as "less than 1 cm"
992	Described as "less than 2 cm," or "greater than 1 cm," or "between 1 cm and 2 cm" Stated as T1, NOS with no documentation of tumor size

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description
993	Described as "less than 3 cm," or "greater than 2 cm," or "between 2 cm and 3 cm" Stated as T2, NOS with no documentation of tumor size
994	Described as "less than 4 cm," or "greater than 3 cm," or "between 3 cm and 4 cm"
995	Described as "less than 5 cm," or "greater than 4 cm," or "between 4 cm and 5 cm"
999	Unknown; size not stated Not documented in patient record

Pancreas: Head

CS Extension (Revised: 11/22/2009)

Note 1: Islets of Langerhans are distributed throughout the pancreas, and, therefore, any extension code can be used.

Note 2: Codes 400-800 are used for contiguous extension of tumor from the site of origin. Discontinuous involvement is coded in CS Mets at DX.

Note 3: If the only information regarding the tumor extension is the physician's statement of the "T" category, assign code 150, 200, 420, or 790. (Refer to CS Tumor Size table for instructions on coding tumor size if assigning code 150 or 200).

Code	Description	TNM 7th	TNM 6th	SS77	SS2000
000	In situ; non-invasive PanIn III Pancreatic Intraepithelial Neoplasia III Stated as Tis, NOS	Tis	Tis	IS	IS
100	Confined to pancreas	^	*	L	L
150	Stated as T1, NOS with no other information on extension	^	*	L	L
200	Stated as T2, NOS with no other information on extension	^	*	L	L
300	Localized, NOS	^	*	L	L
400	Extension to peripancreatic tissue, NOS Fixation to adjacent structures, NOS	T3	T3	RE	RE
420	Stated as T3, NOS	T3	T3	RE	RE
440	Ampulla of Vater Duodenum Extrahepatic bile duct(s)	T3	T3	RE	RE
500	Adjacent stomach Stomach, NOS	T3	T3	RE	RE

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description	TNM 7th	TNM 6th	SS77	SS2000
540	Blood vessel(s) (major): Gastroduodenal artery Hepatic artery Pancreaticoduodenal artery Portal vein Superior mesenteric vein Transverse colon, including hepatic flexure	T3	T3	RE	RE
550	Mesenteric fat Mesentery Mesocolon Peritoneum	T3	T3	RE	D
570	Gallbladder	T3	T3	RE	D
580	Body of stomach	T3	T3	D	RE
590	(580) + [(550) or (570)]	T3	T3	D	D
600	Tumor is inseparable from the superior mesenteric artery Superior mesenteric artery	T4	T4	RE	RE
610	Omentum	T4	T4	RE	D
630	Liver (including porta hepatis)	T4	T4	RE	D
650	(600) + [(550) or (570)]	T4	T4	RE	D
660	(600) + (580)	T4	T4	D	RE
670	(600) + (590) OR Any of [(610) to (650)] + [(580) or (590)] OR (660) + any of [(550) or (570) or (590) or (610) or (630) or (650)]	T4	T4	D	D
680	Tumor is inseparable from the celiac axis Aorta Celiac artery	T4	T4	D	D
690	Colon (other than transverse colon including hepatic flexure) Spleen	T4	T4	D	D
780	Adrenal (suprarenal) gland Ileum Jejunum Kidney Retroperitoneum Ureter	T4	T4	D	D
790	Stated as T4, NOS	T4	T4	D	D

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description	TNM 7th	TNM 6th	SS77	SS2000
800	Further contiguous extension	T4	T4	D	D
950	No evidence of primary tumor	T0	T0	U	U
999	Unknown extension Primary tumor cannot be assessed Not documented in patient record	TX	TX	U	U

^ For Extension codes 100, 150, 200 and 300 ONLY, the T category is assigned based on the value of CS Tumor Size, as shown in the Extension Size Table for this site.

* For Extension codes 100, 150, 200 and 300 ONLY, the T category is assigned based on the value of CS Tumor Size, as shown in the Extension Size Table for this site.

Pancreas: Head

CS Tumor Size/Ext Eval (Revised: 08/10/2009)

Code	Description	Staging Basis
0	Does not meet criteria for AJCC pathologic staging: No surgical resection done. Evaluation based on physical examination, imaging examination, or other non-invasive clinical evidence. No autopsy evidence used.	c
1	Does not meet criteria for AJCC pathologic staging: No surgical resection done. Evaluation based on endoscopic examination, diagnostic biopsy, including fine needle aspiration biopsy, or other invasive techniques, including surgical observation without biopsy. No autopsy evidence used.	c
2	Meets criteria for AJCC pathologic staging: No surgical resection done, but evidence derived from autopsy (tumor was suspected or diagnosed prior to autopsy)	p
3	Either criteria meets AJCC pathologic staging: Surgical resection performed WITHOUT pre-surgical systemic treatment or radiation OR surgical resection performed, unknown if pre-surgical systemic treatment or radiation performed AND Evaluation based on evidence acquired before treatment, supplemented or modified by the additional evidence acquired during and from surgery, particularly from pathologic examination of the resected specimen. No surgical resection done. Evaluation based on positive biopsy of highest T classification.	p
5	Does not meet criteria for AJCC y-pathologic (yp) staging: Surgical resection performed AFTER neoadjuvant therapy and tumor size/extension based on clinical evidence, unless the pathologic evidence at surgery (AFTER neoadjuvant) is more extensive (see code 6).	c

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description	Staging Basis
6	Meets criteria for AJCC y-pathologic (yp) staging: Surgical resection performed AFTER neoadjuvant therapy AND tumor size/extension based on pathologic evidence, because pathologic evidence at surgery is more extensive than clinical evidence before treatment.	yp
8	Meets criteria for autopsy (a) staging: Evidence from autopsy only (tumor was unsuspected or undiagnosed prior to autopsy)	a
9	Unknown if surgical resection done Not assessed; cannot be assessed Unknown if assessed Not documented in patient record	c

Pancreas: Head

CS Lymph Nodes (Revised: 05/15/2009)

Note: Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in the field Mets at DX.

Code	Description	TNM 7	TNM 6	SS77	SS2000
000	No regional lymph node involvement	N0	N0	NONE	NONE
100	Regional lymph nodes: Celiac Gastroepiploic (gastro-omental), left Hepatic Infrapyloric (subpyloric) Lateral aortic (lumbar) Peripancreatic, NOS: Anterior, NOS: Anterior pancreaticoduodenal Anterior proximal mesenteric Pyloric Inferior to the head and body of pancreas Posterior, NOS: Pericholedochal (common bile duct) Posterior pancreaticoduodenal Posterior proximal mesentery Superior to the head and body of pancreas Retroperitoneal Superior mesenteric Regional lymph node(s), NOS Stated as N1, NOS	N1	N1	RN	RN
200	Pancreaticosplenic (pancreaticolienal) Splenic (lienal), NOS Superior hilum Suprapancreatic	N1	N1	D	D
800	Lymph nodes, NOS	N1	N1	RN	RN

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description	TNM 7	TNM 6	SS77	SS2000
999	Unknown; not stated Regional lymph nodes cannot be assessed Not documented in patient record	NX	NX	U	U

Pancreas: Head

CS Lymph Nodes Eval (Revised: 10/26/2009)

Note 1: This field is used primarily to derive the staging basis for the N category in the TNM system. It records how the code for the item "CS Lymph Nodes" was determined based on the diagnostic methods employed and their intent.

Note 2:

In the 7th edition of the AJCC manual, the clinical and pathologic classification rules for the N category were changed to reflect current medical practice. The N is designated as clinical or pathologic based on the intent (workup versus treatment) matching with the assessment of the T classification. When the intent is workup, the staging basis is clinical, and when the intent is treatment, the staging basis is pathologic.

A. Microscopic assessment including biopsy of regional nodes or sentinel nodes if being performed as part of the workup to choose the treatment plan, is therefore part of the clinical staging. When it is part of the workup, the T category is clinical, and there has not been a resection of the primary site adequate for pathologic T classification (which would be part of the treatment).

B. Microscopic assessment of regional nodes if being performed as part of the treatment is therefore part of the pathologic staging. When it is part of the treatment, the T category is pathologic, and there has been a resection of the primary site adequate for pathologic T classification (all part of the treatment).

Note 3: Microscopic assessment of the highest N category is always pathologic (code 3).

Note 4: If lymph node dissection is not performed after neoadjuvant therapy, use code 0 or 1.

Note 5: Only codes 5 and 6 are used if the node assessment is performed after neoadjuvant therapy.

Code	Description	Staging Basis
0	Does not meet criteria for AJCC pathologic staging: No regional lymph nodes removed for examination. Evidence based on physical examination, imaging examination, or other non-invasive clinical evidence. No autopsy evidence used.	c
1	Does not meet criteria for AJCC pathologic staging based on at least one of the following criteria: No regional lymph nodes removed for examination. Evidence based on endoscopic examination, or other invasive techniques including surgical observation, without biopsy. No autopsy evidence used. OR Fine needle aspiration, incisional core needle biopsy, or excisional biopsy of regional lymph nodes or sentinel nodes as part of the diagnostic workup, WITHOUT removal of the primary site adequate for pathologic T classification (treatment).	c
2	Meets criteria for AJCC pathologic staging: No regional lymph nodes removed for examination, but evidence derived from autopsy (tumor was suspected or diagnosed prior to autopsy).	p

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description	Staging Basis
3	Meets criteria for AJCC pathologic staging based on at least one of the following criteria: Any microscopic assessment of regional nodes (including FNA, incisional core needle bx, excisional bx, sentinel node bx or node resection), WITH removal of the primary site adequate for pathologic T classification (treatment) or biopsy assessment of the highest T category. OR Any microscopic assessment of a regional node in the highest N category, regardless of the T category information.	p
5	Does not meet criteria for AJCC y-pathologic (yp) staging: Regional lymph nodes removed for examination AFTER neoadjuvant therapy AND lymph node evaluation based on clinical evidence, unless the pathologic evidence at surgery (AFTER neoadjuvant) is more extensive (see code 6).	c
6	Meets criteria for AJCC y-pathologic (yp) staging: Regional lymph nodes removed for examination AFTER neoadjuvant therapy AND lymph node evaluation based on pathologic evidence, because the pathologic evidence at surgery is more extensive than clinical evidence before treatment.	yp
8	Meets criteria for AJCC autopsy (a) staging: Evidence from autopsy; tumor was unsuspected or undiagnosed prior to autopsy.	a
9	Unknown if lymph nodes removed for examination Not assessed; cannot be assessed Unknown if assessed Not documented in patient record	c

Pancreas: Head

Reg LN Pos (Revised: 03/30/2009)

Note: Record this field even if there has been preoperative treatment.

Code	Description
00	All nodes examined negative.
01-89	1 - 89 nodes positive (code exact number of nodes positive)
90	90 or more nodes positive
95	Positive aspiration or core biopsy of lymph node(s)
97	Positive nodes - number unspecified
98	No nodes examined
99	Unknown if nodes are positive; not applicable Not documented in patient record

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Pancreas: Head

Reg LN Exam (Revised: 03/02/2009)

Code	Description
00	No nodes examined
01-89	1 - 89 nodes examined (code exact number of regional lymph nodes examined)
90	90 or more nodes examined
95	No regional nodes removed, but aspiration or core biopsy of regional nodes performed
96	Regional lymph node removal documented as sampling and number of nodes unknown/not stated
97	Regional lymph node removal documented as dissection and number of nodes unknown/not stated
98	Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection; nodes examined, but number unknown
99	Unknown if nodes were examined; not applicable or negative Not documented in patient record

Pancreas: Head

CS Mets at DX (Revised: 05/14/2009)

Code	Description	TNM 7th	TNM 6th	SS77	SS2000
00	No; none	M0	M0	NONE	NONE
10	Distant lymph node(s)	M1	M1	D	D
40	Distant metastases except distant lymph node(s) (code 10) (includes seeding of peritoneum, even if limited to the lesser sac region; positive peritoneal cytology) Carcinomatosis	M1	M1	D	D
50	(10) + (40) Distant lymph node(s) plus other distant metastases	M1	M1	D	D
60	Distant metastasis, NOS M1, NOS	M1	M1	D	D
99	Unknown if distant metastasis Distant metastasis cannot be assessed Not documented in patient record	M0	MX	U	U

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Pancreas: Head

CS Mets Eval (Revised: 08/10/2009)

Note: This item reflects the validity of the classification of the item CS Mets at DX only according to the diagnostic methods employed.

Code	Description	Staging Basis
0	Does not meet criteria for AJCC pathologic staging of distant metastasis: Evaluation of distant metastasis based on physical examination, imaging examination, and/or other non-invasive clinical evidence. No pathologic examination of metastatic tissue performed or pathologic examination was negative.	c
1	Does not meet criteria for AJCC pathologic staging of distant metastasis: Evaluation of distant metastasis based on endoscopic examination or other invasive technique, including surgical observation without biopsy. No pathologic examination of metastatic tissue performed or pathologic examination was negative.	c
2	Meets criteria for AJCC pathologic staging of distant metastasis: No pathologic examination of metastatic specimen done prior to death, but positive metastatic evidence derived from autopsy (tumor was suspected or diagnosed prior to autopsy).	p
3	Meets criteria for AJCC pathologic staging of distant metastasis: Specimen from metastatic site microscopically positive WITHOUT pre-surgical systemic treatment or radiation OR specimen from metastatic site microscopically positive, unknown if pre-surgical systemic treatment or radiation performed OR specimen from metastatic site microscopically positive prior to neoadjuvant treatment.	p
5	Does not meet criteria for AJCC y-pathologic (yp) staging of distant metastasis: Specimen from metastatic site microscopically positive WITH pre-surgical systemic treatment or radiation, BUT metastasis based on clinical evidence.	c
6	Meets criteria for AJCC y-pathologic (yp) staging of distant metastasis: Specimen from metastatic site microscopically positive WITH pre-surgical systemic treatment or radiation, BUT metastasis based on pathologic evidence.	yp
8	Meets criteria for AJCC autopsy (a) staging of distant metastasis: Evidence from autopsy based on examination of positive metastatic tissue AND tumor was unsuspected or undiagnosed prior to autopsy.	a
9	Not assessed; cannot be assessed Unknown if assessed Not documented in patient record	c

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Pancreas: Head

CS Site-Specific Factor 1 CA 19-9 Lab Value (Revised: 01/27/2010)

Note 1: Carbohydrate Antigen 19-9 is a tumor marker that has value in the management of malignancies.

Note 2: Record in Units/millileter the highest CA 19-9 lab value recorded in the medical record prior to treatment.

Example: A pretreatment CA 19-9 of 60 Units/millileter (U/ml) would be recorded as 60.

Code	Description
000	0 U/ml
001	0.1 or less U/ml
002-979	0.2-97.9 U/ml
980	98.0 or greater U/ml
988	Not applicable: Information not collected for this case (May include cases converted from code 888 used in CSv1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.)
997	Test ordered, results not in chart
998	Test not done (test was not ordered and was not performed)
999	Unknown or no information Not documented in patient record

Pancreas: Head

CS Site-Specific Factor 2 Serum Chromogranin A (CgA) Lab Value (Revised: 12/29/2009)

Note: Record the highest CgA lab value recorded in the medical record prior to treatment. Example: A pretreatment CgA of 90 nanograms/millileter (ng/ml) would be recorded as 090.

Code	Description
000	0 ng/ml
001	1 or less ng/ml
002-979	002-979 ng/ml
980	980 or greater ng/ml
988	Not applicable: Information not collected for this case (May include cases converted from code 888 used in CSv1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.)
997	Test ordered, results not in chart
998	Test not done (test was not ordered and was not performed)
999	Unknown or no information Not documented in patient record

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Pancreas: Head

CS Site-Specific Factor 3 Mitotic Count (Revised: 01/27/2010)

Note: Record mitotic count as documented in the pathology report. For pancreas primaries, this count is usually documented as mitoses per 10 high power fields (40x field). For other sites in which mitotic count is collected, this denominator may vary.

Code	Description
000	0 mitoses per 10 high-power fields (40x field) 0 mitoses per 2 square millimeters Mitoses absent No mitoses present
001	.1 mitoses per 10 high-power fields (40x field) .1 mitoses per 2 square millimeters
002	.2 mitoses per 10 high-power fields (40x field) .2 mitoses per 2 square millimeters
003	.3 mitoses per 10 high-power fields (40x field) .3 mitoses per 2 square millimeters
004	.4 mitoses per 10 high-power fields (40x field) .4 mitoses per 2 square millimeters
005	.5 mitoses per 10 high-power fields (40x field) .5 mitoses per 2 square millimeters
006	.6 mitoses per 10 high-power fields (40x field) .6 mitoses per 2 square millimeters
007	.7 mitoses per 10 high-power fields (40x field) .7 mitoses per 2 square millimeters
008	.8 mitoses per 10 high-power fields (40x field) .8 mitoses per 2 square millimeters
009	.9 mitoses per 10 high-power fields (40x field) .9 mitoses per 2 square millimeters Stated as less than 1 mitoses per 10 high-power fields (40x field) Stated as less than 1 mitoses per 2 square millimeters
010-100	1-10 mitoses per 10 high-power fields (40x field) 1-10 mitoses per 2 square millimeters
110	11 or more mitoses per 10 high-power fields (40x field) 11 or more mitoses per 2 square millimeters
888	OBSOLETE DATA CONVERTED V0200 See code 988: Not applicable for this site
988	Not applicable: Information not collected for this case (May include cases converted from code 888 used in CSv1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.)

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description
990	Specific number not stated, described less than or equal to 4 mitoses per 10 high-power fields (40x field) Specific number not stated, described less than or equal to 4 mitoses per square millimeter
995	Specific number not stated, described as greater than 4 mitoses per 10 high-power fields (40x field) Specific number not stated, described as greater than 4 mitoses per square millimeters
999	Unknown Not stated Not documented in patient record

Pancreas: Head

CS Site-Specific Factor 4 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

Pancreas: Head

CS Site-Specific Factor 5 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

Pancreas: Head

CS Site-Specific Factor 6 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Pancreas: Head

CS Site-Specific Factor 7 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Pancreas: Head

CS Site-Specific Factor 8 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Pancreas: Head

CS Site-Specific Factor 9 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Pancreas: Head

CS Site-Specific Factor 10 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Pancreas: Head

CS Site-Specific Factor 11 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Pancreas: Head

CS Site-Specific Factor 12 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Pancreas: Head

CS Site-Specific Factor 13 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Pancreas: Head

CS Site-Specific Factor 14 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Pancreas: Head

CS Site-Specific Factor 15 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Pancreas: Head

CS Site-Specific Factor 16 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Pancreas: Head

CS Site-Specific Factor 17 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Pancreas: Head

CS Site-Specific Factor 18 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Pancreas: Head

CS Site-Specific Factor 19 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Pancreas: Head

CS Site-Specific Factor 20 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Pancreas: Head

CS Site-Specific Factor 21 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Pancreas: Head

CS Site-Specific Factor 22 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Pancreas: Head

CS Site-Specific Factor 23 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Pancreas: Head

CS Site-Specific Factor 24 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Pancreas: Head

CS Site-Specific Factor 25 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Pancreas: Body and Tail

C25.1-C25.2

C25.1 Body of pancreas

C25.2 Tail of pancreas

Note: For tumors of the islet cells, determine which subsite of the pancreas is involved and use that primary site code and corresponding Collaborative Stage scheme. If the subsite cannot be determined, use the general code for Islets of Langerhans, C25.4, and use the Collaborative Stage scheme for Pancreas, Other and Unspecified.

CS Tumor Size	CS Site-Specific Factor 1 CA 19-9 Lab Value	<p>The following tables are available at the collaborative staging website: Histology Inclusion Table AJCC 7th ed. Histology Exclusion Table AJCC 6th ed. AJCC TNM 7 Stage AJCC TNM 6 Stage Summary Stage Extension Size Table</p>
CS Extension	CS Site-Specific Factor 2 Serum Chromogranin A (CgA) Lab Value	
CS Tumor Size/Ext Eval	CS Site-Specific Factor 3 Mitotic Count	
CS Lymph Nodes	CS Site-Specific Factor 4	
CS Lymph Nodes Eval	CS Site-Specific Factor 5	
Reg LN Pos	CS Site-Specific Factor 6	
Reg LN Exam	CS Site-Specific Factor 7	
CS Mets at DX	CS Site-Specific Factor 8	
CS Mets Eval	CS Site-Specific Factor 9	
	CS Site-Specific Factor 10	
	CS Site-Specific Factor 11	
	CS Site-Specific Factor 12	
	CS Site-Specific Factor 13	
	CS Site-Specific Factor 14	
	CS Site-Specific Factor 15	
	CS Site-Specific Factor 16	
	CS Site-Specific Factor 17	
	CS Site-Specific Factor 18	
	CS Site-Specific Factor 19	
	CS Site-Specific Factor 20	
	CS Site-Specific Factor 21	
	CS Site-Specific Factor 22	
	CS Site-Specific Factor 23	
	CS Site-Specific Factor 24	
	CS Site-Specific Factor 25	

Pancreas: Body and Tail

CS Tumor Size (Revised: 06/08/2009)

Note: Code the specific tumor size as documented in the medical record. If the ONLY information regarding tumor size is the clinician's statement of the "T" category, assign code 992 (T1, NOS) or 993 (T2, NOS). (Refer to the CS Extension table for instructions on coding extension).

Code	Description
000	No mass/tumor found
001-988	001 - 988 millimeters (code exact size in millimeters)
989	989 millimeters or larger
990	Microscopic focus or foci only, no size of focus given
991	Described as "less than 1 cm"
992	Described as "less than 2 cm," or "greater than 1 cm," or "between 1 cm and 2 cm" Stated as T1, NOS with no documentation of tumor size

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description
993	Described as "less than 3 cm," or "greater than 2 cm," or "between 2 cm and 3 cm" Stated as T2, NOS with no documentation of tumor size
994	Described as "less than 4 cm," or "greater than 3 cm," or "between 3 cm and 4 cm"
995	Described as "less than 5 cm," or "greater than 4 cm," or "between 4 cm and 5 cm"
999	Unknown; size not stated Not documented in patient record

Pancreas: Body and Tail

CS Extension (Revised: 09/24/2009)

Note 1: Islets of Langerhans are distributed throughout the pancreas, and, therefore, any extension code can be used.

Note 2: Codes 400-800 are used for contiguous extension of tumor from the site of origin. Discontinuous involvement is coded in CS Mets at DX.

Note 3: If the only information regarding the tumor extension is the physician's statement of the "T" category, assign code 150, 200, 420, or 790. (Refer to CS Tumor Size table for instructions on coding tumor size if assigning code 150 or 200).

Code	Description	TNM 7	TNM 6	SS77	SS2000
000	In situ; non-invasive PanIn III Pancreatic Intraepithelial Neoplasia III Stated as Tis, NOS	Tis	Tis	IS	IS
100	Confined to pancreas	^	*	L	L
150	Stated as T1, NOS with no other information on extension	^	*	L	L
200	Stated as T2, NOS with no other information on extension	^	*	L	L
300	Localized, NOS	^	*	L	L
400	Extension to peripancreatic tissue, NOS Fixation to adjacent structures, NOS	T3	T3	RE	RE
420	Stated as T3, NOS	T3	T3	RE	RE
440	Duodenum	T3	T3	RE	RE
480	Ampulla of Vater Extrahepatic bile duct(s)	T3	T3	RE	RE
500	Spleen	T3	T3	RE	RE
560	Blood vessel(s): Hepatic artery Portal vein Splenic artery/vein Superior mesenteric vein Splenic flexure of colon	T3	T3	RE	RE

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description	TNM 7	TNM 6	SS77	SS2000
570	Kidney, NOS Left adrenal (suprarenal) gland Left kidney Left ureter	T3	T3	RE	D
580	Mesenteric fat Mesentery Mesocolon Peritoneum	T3	T3	RE	D
590	Retroperitoneal soft tissue (retroperitoneal space)	T3	T3	D	D
600	Tumor is inseparable from the celiac axis or superior mesenteric artery Aorta Celiac artery Superior mesenteric artery	T4	T4	RE	RE
620	Stomach	T4	T4	RE	RE
700	[(600) or (620)] + [(570) or (580)]	T4	T4	RE	D
710	Ileum Jejunum	T4	T4	RE	D
730	Gallbladder Liver (including porta hepatis)	T4	T4	RE	D
750	(590) + any of [(600) or (620) or (710) or (730)]	T4	T4	D	D
770	Colon (other than splenic flexure)	T4	T4	D	D
780	Diaphragm Right adrenal (suprarenal) gland Right kidney Right ureter	T4	T4	D	D
790	Stated as T4, NOS	T4	T4	D	D
800	Further contiguous extension	T4	T4	D	D
950	No evidence of primary tumor	T0	T0	U	U
999	Unknown extension Primary tumor cannot be assessed Not documented in patient record	TX	TX	U	U

^ For Extension codes 100, 200 and 300 ONLY, the T category is assigned based on the value of CS Tumor Size, as shown in the Extension Size Table for this site.

* For Extension codes 100, 150, 200, and 300 ONLY, the T category is assigned based on the value of CS Tumor Size, as shown in the Extension Size Table for this site.

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Pancreas: Body and Tail

CS Tumor Size/Ext Eval (Revised: 08/10/2009)

Code	Description	Staging Basis
0	Does not meet criteria for AJCC pathologic staging: No surgical resection done. Evaluation based on physical examination, imaging examination, or other non-invasive clinical evidence. No autopsy evidence used.	c
1	Does not meet criteria for AJCC pathologic staging: No surgical resection done. Evaluation based on endoscopic examination, diagnostic biopsy, including fine needle aspiration biopsy, or other invasive techniques, including surgical observation without biopsy. No autopsy evidence used.	c
2	Meets criteria for AJCC pathologic staging: No surgical resection done, but evidence derived from autopsy (tumor was suspected or diagnosed prior to autopsy)	p
3	Either criteria meets AJCC pathologic staging: Surgical resection performed WITHOUT pre-surgical systemic treatment or radiation OR surgical resection performed, unknown if pre-surgical systemic treatment or radiation performed AND Evaluation based on evidence acquired before treatment, supplemented or modified by the additional evidence acquired during and from surgery, particularly from pathologic examination of the resected specimen. No surgical resection done. Evaluation based on positive biopsy of highest T classification.	p
5	Does not meet criteria for AJCC y-pathologic (yp) staging: Surgical resection performed AFTER neoadjuvant therapy and tumor size/extension based on clinical evidence, unless the pathologic evidence at surgery (AFTER neoadjuvant) is more extensive (see code 6).	c
6	Meets criteria for AJCC y-pathologic (yp) staging: Surgical resection performed AFTER neoadjuvant therapy AND tumor size/extension based on pathologic evidence, because pathologic evidence at surgery is more extensive than clinical evidence before treatment.	yp
8	Meets criteria for autopsy (a) staging: Evidence from autopsy only (tumor was unsuspected or undiagnosed prior to autopsy)	a
9	Unknown if surgical resection done Not assessed; cannot be assessed Unknown if assessed Not documented in patient record	c

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Pancreas: Body and Tail

CS Lymph Nodes (Revised: 05/15/2009)

Note: Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in the field Mets at DX.

Code	Description	TNM 7th	TNM 6th	SS77	SS2000
000	No regional lymph node involvement	N0	N0	NONE	NONE
100	Regional lymph node(s): Hepatic Lateral aortic (lumbar) Pancreaticosplenic (pancreaticolienal) Peripancreatic, NOS: Anterior, NOS: Anterior pancreaticoduodenal Anterior proximal mesenteric Pyloric Inferior to the head and body of pancreas Posterior, NOS: Pericholedochal (common bile duct) Posterior pancreaticoduodenal Posterior proximal mesentery Superior to the head and body of pancreas Retroperitoneal Splenic (lienal) Gastroepiploic Splenic hilum Suprapancreatic Superior mesenteric Regional lymph node(s), NOS Stated as N1, NOS	N1	N1	RN	RN
200	Regional lymph node(s): Celiac Infrapyloric (subpyloric)	N1	N1	D	D
800	Lymph nodes, NOS	N1	N1	RN	RN
999	Unknown; not stated Regional lymph node(s) cannot be assessed Not documented in patient record	NX	NX	U	U

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Pancreas: Body and Tail

CS Lymph Nodes Eval (Revised: 10/26/2009)

Note 1: This field is used primarily to derive the staging basis for the N category in the TNM system. It records how the code for the item "CS Lymph Nodes" was determined based on the diagnostic methods employed and their intent.

Note 2:

In the 7th edition of the AJCC manual, the clinical and pathologic classification rules for the N category were changed to reflect current medical practice. The N is designated as clinical or pathologic based on the intent (workup versus treatment) matching with the assessment of the T classification. When the intent is workup, the staging basis is clinical, and when the intent is treatment, the staging basis is pathologic.

A. Microscopic assessment including biopsy of regional nodes or sentinel nodes if being performed as part of the workup to choose the treatment plan, is therefore part of the clinical staging. When it is part of the workup, the T category is clinical, and there has not been a resection of the primary site adequate for pathologic T classification (which would be part of the treatment).

B. Microscopic assessment of regional nodes if being performed as part of the treatment is therefore part of the pathologic staging. When it is part of the treatment, the T category is pathologic, and there has been a resection of the primary site adequate for pathologic T classification (all part of the treatment).

Note 3: Microscopic assessment of the highest N category is always pathologic (code 3).

Note 4: If lymph node dissection is not performed after neoadjuvant therapy, use code 0 or 1.

Note 5: Only codes 5 and 6 are used if the node assessment is performed after neoadjuvant therapy.

Code	Description	Staging Basis
0	Does not meet criteria for AJCC pathologic staging: No regional lymph nodes removed for examination. Evidence based on physical examination, imaging examination, or other non-invasive clinical evidence. No autopsy evidence used.	c
1	Does not meet criteria for AJCC pathologic staging based on at least one of the following criteria: No regional lymph nodes removed for examination. Evidence based on endoscopic examination, or other invasive techniques including surgical observation, without biopsy. No autopsy evidence used. OR Fine needle aspiration, incisional core needle biopsy, or excisional biopsy of regional lymph nodes or sentinel nodes as part of the diagnostic workup, WITHOUT removal of the primary site adequate for pathologic T classification (treatment).	c
2	Meets criteria for AJCC pathologic staging: No regional lymph nodes removed for examination, but evidence derived from autopsy (tumor was suspected or diagnosed prior to autopsy).	p
3	Meets criteria for AJCC pathologic staging based on at least one of the following criteria: Any microscopic assessment of regional nodes (including FNA, incisional core needle bx, excisional bx, sentinel node bx or node resection), WITH removal of the primary site adequate for pathologic T classification (treatment) or biopsy assessment of the highest T category. OR Any microscopic assessment of a regional node in the highest N category, regardless of the T category information.	p

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description	Staging Basis
5	Does not meet criteria for AJCC y-pathologic (yp) staging: Regional lymph nodes removed for examination AFTER neoadjuvant therapy AND lymph node evaluation based on clinical evidence, unless the pathologic evidence at surgery (AFTER neoadjuvant) is more extensive (see code 6).	c
6	Meets criteria for AJCC y-pathologic (yp) staging: Regional lymph nodes removed for examination AFTER neoadjuvant therapy AND lymph node evaluation based on pathologic evidence, because the pathologic evidence at surgery is more extensive than clinical evidence before treatment.	yp
8	Meets criteria for AJCC autopsy (a) staging: Evidence from autopsy; tumor was unsuspected or undiagnosed prior to autopsy.	a
9	Unknown if lymph nodes removed for examination Not assessed; cannot be assessed Unknown if assessed Not documented in patient record	c

Pancreas: Body and Tail

Reg LN Pos (Revised: 03/30/2009)

Note: Record this field even if there has been preoperative treatment.

Code	Description
00	All nodes examined negative.
01-89	1 - 89 nodes positive (code exact number of nodes positive)
90	90 or more nodes positive
95	Positive aspiration or core biopsy of lymph node(s)
97	Positive nodes - number unspecified
98	No nodes examined
99	Unknown if nodes are positive; not applicable Not documented in patient record

Pancreas: Body and Tail

Reg LN Exam (Revised: 03/02/2009)

Code	Description
00	No nodes examined
01-89	1 - 89 nodes examined (code exact number of regional lymph nodes examined)
90	90 or more nodes examined

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description
95	No regional nodes removed, but aspiration or core biopsy of regional nodes performed
96	Regional lymph node removal documented as sampling and number of nodes unknown/not stated
97	Regional lymph node removal documented as dissection and number of nodes unknown/not stated
98	Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection; nodes examined, but number unknown
99	Unknown if nodes were examined; not applicable or negative Not documented in patient record

Pancreas: Body and Tail

CS Mets at DX (Revised: 08/13/2009)

Code	Description	TNM 7th	TNM 6th	SS77	SS2000
00	No; none	M0	M0	NONE	NONE
10	Distant lymph node(s) Distant lymph node(s) , NOS	M1	M1	D	D
40	Distant metastases except distant lymph node(s) (code 10) (includes seeding of peritoneum, even if limited to the lesser sac region; positive peritoneal cytology) Carcinomatosis	M1	M1	D	D
50	(10) + (40) Distant lymph node(s) plus other distant metastases	M1	M1	D	D
60	Distant metastasis, NOS M1, NOS	M1	M1	D	D
99	Unknown if distant metastasis Distant metastasis cannot be assessed Not documented in patient record	M0	MX	U	U

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Pancreas: Body and Tail

CS Mets Eval (Revised: 08/10/2009)

Note: This item reflects the validity of the classification of the item CS Mets at DX only according to the diagnostic methods employed.

Code	Description	Staging Basis
0	Does not meet criteria for AJCC pathologic staging of distant metastasis: Evaluation of distant metastasis based on physical examination, imaging examination, and/or other non-invasive clinical evidence. No pathologic examination of metastatic tissue performed or pathologic examination was negative.	c
1	Does not meet criteria for AJCC pathologic staging of distant metastasis: Evaluation of distant metastasis based on endoscopic examination or other invasive technique, including surgical observation without biopsy. No pathologic examination of metastatic tissue performed or pathologic examination was negative.	c
2	Meets criteria for AJCC pathologic staging of distant metastasis: No pathologic examination of metastatic specimen done prior to death, but positive metastatic evidence derived from autopsy (tumor was suspected or diagnosed prior to autopsy).	p
3	Meets criteria for AJCC pathologic staging of distant metastasis: Specimen from metastatic site microscopically positive WITHOUT pre-surgical systemic treatment or radiation OR specimen from metastatic site microscopically positive, unknown if pre-surgical systemic treatment or radiation performed OR specimen from metastatic site microscopically positive prior to neoadjuvant treatment.	p
5	Does not meet criteria for AJCC y-pathologic (yp) staging of distant metastasis: Specimen from metastatic site microscopically positive WITH pre-surgical systemic treatment or radiation, BUT metastasis based on clinical evidence.	c
6	Meets criteria for AJCC y-pathologic (yp) staging of distant metastasis: Specimen from metastatic site microscopically positive WITH pre-surgical systemic treatment or radiation, BUT metastasis based on pathologic evidence.	yp
8	Meets criteria for AJCC autopsy (a) staging of distant metastasis: Evidence from autopsy based on examination of positive metastatic tissue AND tumor was unsuspected or undiagnosed prior to autopsy.	a
9	Not assessed; cannot be assessed Unknown if assessed Not documented in patient record	c

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Pancreas: Body and Tail

CS Site-Specific Factor 1 CA 19-9 Lab Value (Revised: 01/27/2010)

Note 1: Carbohydrate Antigen 19-9 is a tumor marker that has value in the management of certain malignancies.

Note 2: Record in Units/millileter the highest CA 19-9 lab value recorded in the medical record prior to treatment.

Example: A pretreatment CA 19-9 of 60 Units/millileter (U/ml) would be recorded as 60.

Code	Description
000	0 U/ml
001	0.1 or less U/ml
002-979	0.2-97.9 U/ml
980	98.0 or greater U/ml
988	Not applicable: Information not collected for this case (May include cases converted from code 888 used in CSv1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.)
997	Test ordered, results not in chart
998	Test not done (test was not ordered and was not performed)
999	Unknown or no information Not documented in patient record

Pancreas: Body and Tail

CS Site-Specific Factor 2 Serum Chromogranin A (CgA) Lab Value (Revised: 12/29/2009)

Note: Record the highest CgA lab value recorded in the medical record prior to treatment. Example: A pretreatment CgA of 90 nanograms/millileter (ng/ml) would be recorded as 090.

Code	Description
000	0 ng/ml
001	1 or less ng/ml
002-979	002-979 ng/ml
980	980 or greater ng/ml
988	Not applicable: Information not collected for this case (May include cases converted from code 888 used in CSv1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.)
997	Test ordered, results not in chart
998	Test not done (test was not ordered and was not performed)
999	Unknown or no information Not documented in patient record

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Pancreas: Body and Tail

CS Site-Specific Factor 3 Mitotic Count (Revised: 01/27/2010)

Note: Record mitotic count as documented in the pathology report. For pancreas primaries, this count is usually documented as mitoses per 10 high power fields (40x field). For other sites in which mitotic count is collected, this denominator may vary.

Code	Description
000	0 mitoses per 10 high-power fields (40x field) 0 mitoses per 2 square millimeters Mitoses absent No mitoses present
001	.1 mitoses per 10 high-power fields (40x field) .1 mitoses per 2 square millimeters
002	.2 mitoses per 10 high-power fields (40x field) .2 mitoses per 2 square millimeters
003	.3 mitoses per 10 high-power fields (40x field) .3 mitoses per 2 square millimeters
004	.4 mitoses per 10 high-power fields (40x field) .4 mitoses per 2 square millimeters
005	.5 mitoses per 10 high-power fields (40x field) .5 mitoses per 2 square millimeters
006	.6 mitoses per 10 high-power fields (40x field) .6 mitoses per 2 square millimeters
007	.7 mitoses per 10 high-power fields (40x field) .7 mitoses per 2 square millimeters
008	.8 mitoses per 10 high-power fields (40x field) .8 mitoses per 2 square millimeters
009	.9 mitoses per 10 high-power fields (40x field) .9 mitoses per 2 square millimeters Stated as less than 1 mitoses per 10 high-power fields (40x field) Stated as less than 1 mitoses per 2 square millimeters
010-100	1-10 mitoses per 10 high-power fields (40x field) 1-10 mitoses per 2 square millimeters
110	11 or more mitoses per 10 high-power fields (40x field) 11 or more mitoses per 2 square millimeters
888	OBSOLETE DATA CONVERTED V0200 See code 988: Not applicable for this site
988	Not applicable: Information not collected for this case (May include cases converted from code 888 used in CSv1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.)

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description
990	Specific number not stated, described less than or equal to 4 mitoses per 10 high-power fields (40x field) Specific number not stated, described less than or equal to 4 mitoses per square millimeter
995	Specific number not stated, described as greater than 4 mitoses per 10 high-power fields (40x field) Specific number not stated, described as greater than 4 mitoses per square millimeters
999	Unknown Not stated Not documented in patient record

Pancreas: Body and Tail

CS Site-Specific Factor 4 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

Pancreas: Body and Tail

CS Site-Specific Factor 5 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

Pancreas: Body and Tail

CS Site-Specific Factor 6 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Pancreas: Body and Tail

CS Site-Specific Factor 7 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Pancreas: Body and Tail

CS Site-Specific Factor 8 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Pancreas: Body and Tail

CS Site-Specific Factor 9 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Pancreas: Body and Tail

CS Site-Specific Factor 10 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Pancreas: Body and Tail

CS Site-Specific Factor 11 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Pancreas: Body and Tail

CS Site-Specific Factor 12 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Pancreas: Body and Tail

CS Site-Specific Factor 13 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Pancreas: Body and Tail

CS Site-Specific Factor 14 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Pancreas: Body and Tail

CS Site-Specific Factor 15 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Pancreas: Body and Tail

CS Site-Specific Factor 16 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Pancreas: Body and Tail

CS Site-Specific Factor 17 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Pancreas: Body and Tail

CS Site-Specific Factor 18 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Pancreas: Body and Tail

CS Site-Specific Factor 19 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Pancreas: Body and Tail

CS Site-Specific Factor 20 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Pancreas: Body and Tail

CS Site-Specific Factor 21 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Pancreas: Body and Tail

CS Site-Specific Factor 22 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Pancreas: Body and Tail

CS Site-Specific Factor 23 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Pancreas: Body and Tail

CS Site-Specific Factor 24 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Pancreas: Body and Tail

CS Site-Specific Factor 25 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Pancreas: Other and Unspecified

C25.3-C25.4, C25.7-C25.9

- C25.3 Pancreatic duct
- C25.4 Islets of Langerhans
- C25.7 Other specified parts of pancreas
- C25.8 Overlapping lesion of pancreas
- C25.9 Pancreas, NOS

Note: For tumors of the islet cells, determine which subsite of the pancreas is involved and use that primary site code and the corresponding Collaborative Stage scheme. If the subsite cannot be determined, use the general code for Islets of Langerhans, C25.4, and use the Collaborative Stage scheme for Pancreas, Other and Unspecified.

CS Tumor Size	CS Site-Specific Factor 1 CA 19-9 Lab Value	The following tables are available at the collaborative staging website: Histology Inclusion Table AJCC 7th ed. Histology Exclusion Table AJCC 6th ed. AJCC TNM 7 Stage AJCC TNM 6 Stage Summary Stage Extension Size Table
CS Extension	CS Site-Specific Factor 2 Serum Chromogranin A (CgA) Lab Value	
CS Tumor Size/Ext Eval	CS Site-Specific Factor 3 Mitotic Count	
CS Lymph Nodes	CS Site-Specific Factor 4	
CS Lymph Nodes Eval	CS Site-Specific Factor 5	
Reg LN Pos	CS Site-Specific Factor 6	
Reg LN Exam	CS Site-Specific Factor 7	
CS Mets at DX	CS Site-Specific Factor 8	
CS Mets Eval	CS Site-Specific Factor 9	
	CS Site-Specific Factor 10	
	CS Site-Specific Factor 11	
	CS Site-Specific Factor 12	
	CS Site-Specific Factor 13	
	CS Site-Specific Factor 14	
	CS Site-Specific Factor 15	
	CS Site-Specific Factor 16	
	CS Site-Specific Factor 17	
	CS Site-Specific Factor 18	
	CS Site-Specific Factor 19	
	CS Site-Specific Factor 20	
	CS Site-Specific Factor 21	
	CS Site-Specific Factor 22	
	CS Site-Specific Factor 23	
	CS Site-Specific Factor 24	
	CS Site-Specific Factor 25	

Pancreas: Other and Unspecified

CS Tumor Size (Revised: 06/08/2009)

Note: Code the specific tumor size as documented in the medical record. If the ONLY information regarding tumor size is the clinician's statement of the "T" category, assign code 992 (T1, NOS) or 993 (T2, NOS). (Refer to the CS Extension table for instructions on coding extension).

Code	Description
000	No mass/tumor found
001-988	001 - 988 millimeters (code exact size in millimeters)
989	989 millimeters or larger
990	Microscopic focus or foci only, no size of focus given
991	Described as "less than 1 cm"

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description
992	Described as "less than 2 cm," or "greater than 1 cm," or "between 1 cm and 2 cm" Stated as T1, NOS with no documentation of tumor size
993	Described as "less than 3 cm," or "greater than 2 cm," or "between 2 cm and 3 cm" Stated as T2, NOS with no documentation of tumor size
994	Described as "less than 4 cm," or "greater than 3 cm," or "between 3 cm and 4 cm"
995	Described as "less than 5 cm," or "greater than 4 cm," or "between 4 cm and 5 cm"
999	Unknown; size not stated Not documented in patient record

Pancreas: Other and Unspecified

CS Extension (Revised: 06/30/2009)

Note 1: Islets of Langerhans are distributed throughout the pancreas, and, therefore, any extension code can be used.

Note 2: Codes 400-800 are used for contiguous extension of tumor from the site of origin. Discontinuous involvement is coded in CS Mets at DX.

Note 3: If the only information regarding the tumor extension is the physicians's statement of the "T" category, assign code 150, 200, 420, or 790. (Refer to CS Tumor Size table for instructions on coding tumor size if assigning code 150 or 200).

Code	Description	TNM 7th	TNM 6th	SS77	SS2000
000	In situ; non-invasive PanIn III Pancreatic intraepithelial neoplasia III Stated as Tis, NOS	Tis	Tis	IS	IS
100	Confined to pancreas	^	*	L	L
150	Stated as T1, NOS with no other information on extension	^	*	L	L
200	Stated as T2, NOS with no other information on extension	^	*	L	L
300	Localized, NOS	^	*	L	L
400	Peripancreatic tissue	T3	T3	RE	RE
420	Stated as T3, NOS	T3	T3	RE	RE
450	Ampulla of Vater Duodenum Extra hepatic bile duct(s)	T3	T3	RE	RE
500	Adjacent large vessel(s) (except as listed in code 600) Colon Spleen Stomach	T3	T3	RE	RE

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description	TNM 7th	TNM 6th	SS77	SS2000
600	Tumor is inseparable from the celiac axis or superior mesenteric artery Aorta Celiac artery Superior mesenteric artery	T4	T4	RE	RE
790	Stated as T4, NOS	T4	T4	D	D
800	Further contiguous extension	T4	T4	D	D
950	No evidence of primary tumor	T0	T0	U	U
999	Unknown extension Primary tumor cannot be assessed Not documented in patient record	TX	TX	U	U

^ For Extension codes 100, 150, 200 and 300 ONLY, the T category is assigned based on the value of CS Tumor Size, as shown in the Extension Size Table for this site.

* For Extension codes 100, 150, 200 and 300 ONLY, the T category is assigned based on the value of CS Tumor Size, as shown in the Extension Size Table for this site.

Pancreas: Other and Unspecified

CS Tumor Size/Ext Eval (Revised: 08/10/2009)

Code	Description	Staging Basis
0	Does not meet criteria for AJCC pathologic staging: No surgical resection done. Evaluation based on physical examination, imaging examination, or other non-invasive clinical evidence. No autopsy evidence used.	c
1	Does not meet criteria for AJCC pathologic staging: No surgical resection done. Evaluation based on endoscopic examination, diagnostic biopsy, including fine needle aspiration biopsy, or other invasive techniques, including surgical observation without biopsy. No autopsy evidence used.	c
2	Meets criteria for AJCC pathologic staging: No surgical resection done, but evidence derived from autopsy (tumor was suspected or diagnosed prior to autopsy)	p
3	Either criteria meets AJCC pathologic staging: Surgical resection performed WITHOUT pre-surgical systemic treatment or radiation OR surgical resection performed, unknown if pre-surgical systemic treatment or radiation performed AND Evaluation based on evidence acquired before treatment, supplemented or modified by the additional evidence acquired during and from surgery, particularly from pathologic examination of the resected specimen. No surgical resection done. Evaluation based on positive biopsy of highest T classification.	p

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description	Staging Basis
5	Does not meet criteria for AJCC y-pathologic (yp) staging: Surgical resection performed AFTER neoadjuvant therapy and tumor size/extension based on clinical evidence, unless the pathologic evidence at surgery (AFTER neoadjuvant) is more extensive (see code 6).	c
6	Meets criteria for AJCC y-pathologic (yp) staging: Surgical resection performed AFTER neoadjuvant therapy AND tumor size/extension based on pathologic evidence, because pathologic evidence at surgery is more extensive than clinical evidence before treatment.	yp
8	Meets criteria for autopsy (a) staging: Evidence from autopsy only (tumor was unsuspected or undiagnosed prior to autopsy)	a
9	Unknown if surgical resection done Not assessed; cannot be assessed Unknown if assessed Not documented in patient record	c

Pancreas: Other and Unspecified

CS Lymph Nodes (Revised: 08/13/2009)

Note: Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in the field Mets at DX.

Code	Description	TNM 7th	TNM 6th	SS77	SS2000
000	No regional lymph node involvement	N0	N0	NONE	NONE

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description	TNM 7th	TNM 6th	SS77	SS2000
100	Regional lymph node(s): Celiac Hepatic Infrapyloric (subpyloric) Lateral aortic (lumbar) Pancreaticosplenic (pancreaticolienal) Peripancreatic, NOS: Anterior, NOS: Anterior pancreaticoduodenal Anterior proximal mesenteric Pyloric Inferior to the head and body of pancreas Posterior, NOS: Pericholedochal (common bile duct) Posterior pancreaticoduodenal Posterior proximal mesentery Superior to the head and body of pancreas Retroperitoneal Splenic (lienal), NOS Gastroepiploic (gastro-omental), left Splenic hilum Suprapancreatic Superior mesenteric Regional lymph node(s), NOS Stated as N1, NOS	N1	N1	RN	RN
800	Lymph nodes, NOS	N1	N1	RN	RN
999	Unknown; not stated Regional lymph nodes cannot be assessed Not documented in patient record	NX	NX	U	U

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Pancreas: Other and Unspecified

CS Lymph Nodes Eval (Revised: 10/26/2009)

Note 1: This field is used primarily to derive the staging basis for the N category in the TNM system. It records how the code for the item "CS Lymph Nodes" was determined based on the diagnostic methods employed and their intent.

Note 2:

In the 7th edition of the AJCC manual, the clinical and pathologic classification rules for the N category were changed to reflect current medical practice. The N is designated as clinical or pathologic based on the intent (workup versus treatment) matching with the assessment of the T classification. When the intent is workup, the staging basis is clinical, and when the intent is treatment, the staging basis is pathologic.

A. Microscopic assessment including biopsy of regional nodes or sentinel nodes if being performed as part of the workup to choose the treatment plan, is therefore part of the clinical staging. When it is part of the workup, the T category is clinical, and there has not been a resection of the primary site adequate for pathologic T classification (which would be part of the treatment).

B. Microscopic assessment of regional nodes if being performed as part of the treatment is therefore part of the pathologic staging. When it is part of the treatment, the T category is pathologic, and there has been a resection of the primary site adequate for pathologic T classification (all part of the treatment).

Note 3: Microscopic assessment of the highest N category is always pathologic (code 3).

Note 4: If lymph node dissection is not performed after neoadjuvant therapy, use code 0 or 1.

Note 5: Only codes 5 and 6 are used if the node assessment is performed after neoadjuvant therapy.

Code	Description	Staging Basis
0	Does not meet criteria for AJCC pathologic staging: No regional lymph nodes removed for examination. Evidence based on physical examination, imaging examination, or other non-invasive clinical evidence. No autopsy evidence used.	c
1	Does not meet criteria for AJCC pathologic staging based on at least one of the following criteria: No regional lymph nodes removed for examination. Evidence based on endoscopic examination, or other invasive techniques including surgical observation, without biopsy. No autopsy evidence used. OR Fine needle aspiration, incisional core needle biopsy, or excisional biopsy of regional lymph nodes or sentinel nodes as part of the diagnostic workup, WITHOUT removal of the primary site adequate for pathologic T classification (treatment).	c
2	Meets criteria for AJCC pathologic staging: No regional lymph nodes removed for examination, but evidence derived from autopsy (tumor was suspected or diagnosed prior to autopsy).	p
3	Meets criteria for AJCC pathologic staging based on at least one of the following criteria: Any microscopic assessment of regional nodes (including FNA, incisional core needle bx, excisional bx, sentinel node bx or node resection), WITH removal of the primary site adequate for pathologic T classification (treatment) or biopsy assessment of the highest T category. OR Any microscopic assessment of a regional node in the highest N category, regardless of the T category information.	p

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description	Staging Basis
5	Does not meet criteria for AJCC y-pathologic (yp) staging: Regional lymph nodes removed for examination AFTER neoadjuvant therapy AND lymph node evaluation based on clinical evidence, unless the pathologic evidence at surgery (AFTER neoadjuvant) is more extensive (see code 6).	c
6	Meets criteria for AJCC y-pathologic (yp) staging: Regional lymph nodes removed for examination AFTER neoadjuvant therapy AND lymph node evaluation based on pathologic evidence, because the pathologic evidence at surgery is more extensive than clinical evidence before treatment.	yp
8	Meets criteria for AJCC autopsy (a) staging: Evidence from autopsy; tumor was unsuspected or undiagnosed prior to autopsy.	a
9	Unknown if lymph nodes removed for examination Not assessed; cannot be assessed Unknown if assessed Not documented in patient record	c

Pancreas: Other and Unspecified

Reg LN Pos (Revised: 03/30/2009)

Note: Record this field even if there has been preoperative treatment.

Code	Description
00	All nodes examined negative.
01-89	1 - 89 nodes positive (code exact number of nodes positive)
90	90 or more nodes positive
95	Positive aspiration or core biopsy of lymph node(s)
97	Positive nodes - number unspecified
98	No nodes examined
99	Unknown if nodes are positive; not applicable Not documented in patient record

Pancreas: Other and Unspecified

Reg LN Exam (Revised: 03/02/2009)

Code	Description
00	No nodes examined
01-89	1 - 89 nodes examined (code exact number of regional lymph nodes examined)
90	90 or more nodes examined

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description
95	No regional nodes removed, but aspiration or core biopsy of regional nodes performed
96	Regional lymph node removal documented as sampling and number of nodes unknown/not stated
97	Regional lymph node removal documented as dissection and number of nodes unknown/not stated
98	Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection; nodes examined, but number unknown
99	Unknown if nodes were examined; not applicable or negative Not documented in patient record

Pancreas: Other and Unspecified

CS Mets at DX (Revised: 05/15/2009)

Code	Description	TNM 7th	TNM 6th	SS77	SS2000
00	No; none	M0	M0	NONE	NONE
10	Distant lymph node(s) Distant lymph node(s), NOS	M1	M1	D	D
40	Distant metastases except distant lymph node(s) (code 10) (includes seeding of peritoneum, even if limited to the lesser sac region; positive peritoneal cytology) Carcinomatosis	M1	M1	D	D
50	(10) + (40) Distant lymph node(s) plus other distant metastases	M1	M1	D	D
60	Distant metastasis, NOS M1, NOS	M1	M1	D	D
99	Unknown if distant metastasis Distant metastasis cannot be assessed Not documented in patient record	M0	MX	U	U

Pancreas: Other and Unspecified

CS Mets Eval (Revised: 08/10/2009)

Note: This item reflects the validity of the classification of the item CS Mets at DX only according to the diagnostic methods employed.

Code	Description	Staging Basis
0	Does not meet criteria for AJCC pathologic staging of distant metastasis: Evaluation of distant metastasis based on physical examination, imaging examination, and/or other non-invasive clinical evidence. No pathologic examination of metastatic tissue performed or pathologic examination was negative.	c

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description	Staging Basis
1	Does not meet criteria for AJCC pathologic staging of distant metastasis: Evaluation of distant metastasis based on endoscopic examination or other invasive technique, including surgical observation without biopsy. No pathologic examination of metastatic tissue performed or pathologic examination was negative.	c
2	Meets criteria for AJCC pathologic staging of distant metastasis: No pathologic examination of metastatic specimen done prior to death, but positive metastatic evidence derived from autopsy (tumor was suspected or diagnosed prior to autopsy).	p
3	Meets criteria for AJCC pathologic staging of distant metastasis: Specimen from metastatic site microscopically positive WITHOUT pre-surgical systemic treatment or radiation OR specimen from metastatic site microscopically positive, unknown if pre-surgical systemic treatment or radiation performed OR specimen from metastatic site microscopically positive prior to neoadjuvant treatment.	p
5	Does not meet criteria for AJCC y-pathologic (yp) staging of distant metastasis: Specimen from metastatic site microscopically positive WITH pre-surgical systemic treatment or radiation, BUT metastasis based on clinical evidence.	c
6	Meets criteria for AJCC y-pathologic (yp) staging of distant metastasis: Specimen from metastatic site microscopically positive WITH pre-surgical systemic treatment or radiation, BUT metastasis based on pathologic evidence.	yp
8	Meets criteria for AJCC autopsy (a) staging of distant metastasis: Evidence from autopsy based on examination of positive metastatic tissue AND tumor was unsuspected or undiagnosed prior to autopsy.	a
9	Not assessed; cannot be assessed Unknown if assessed Not documented in patient record	c

Pancreas: Other and Unspecified

CS Site-Specific Factor 1 CA 19-9 Lab Value (Revised: 01/27/2010)

Note 1: Carbohydrate Antigen 19-9 is a tumor marker that has value in the management of certain malignancies.

Note 2: Record in Units/millileter the highest CA 19-9 lab value recorded in the medical record prior to treatment.

Example: A pretreatment CA 19-9 of 60 Units/millileter (U/ml) would be recorded as 60.

Code	Description
000	0 U/ml
001	0.1 or less U/ml
002-979	0.2-97.9 U/ml
980	98.0 or greater U/ml

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description
988	Not applicable: Information not collected for this case (May include cases converted from code 888 used in CSv1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.)
997	Test ordered, results not in chart
998	Test not done (test was not ordered and was not performed)
999	Unknown or no information Not documented in patient record

Pancreas: Other and Unspecified

CS Site-Specific Factor 2 Serum Chromogranin A (CgA) Lab Value (Revised: 12/29/2009)

Note: Record the highest CgA lab value recorded in the medical record prior to treatment. Example: A pretreatment CgA of 90 nanograms/millileter (ng/ml) would be recorded as 090.

Code	Description
000	0 ng/ml
001	1 or less ng/ml
002-979	002-979 ng/ml
980	980 or greater ng/ml
988	Not applicable: Information not collected for this case (May include cases converted from code 888 used in CSv1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.)
997	Test ordered, results not in chart
998	Test not done (test was not ordered and was not performed)
999	Unknown or no information Not documented in patient record

Pancreas: Other and Unspecified

CS Site-Specific Factor 3 Mitotic Count (Revised: 01/27/2010)

Note: Record mitotic count as documented in the pathology report. For pancreas primaries, this count is usually documented as mitoses per 10 high power fields (40x field). For other sites in which mitotic count is collected, this denominator may vary.

Code	Description
000	0 mitoses per 10 high-power fields (40x field) 0 mitoses per 2 square millimeters Mitoses absent No mitoses present
001	.1 mitoses per 10 high-power fields (40x field) .1 mitoses per 2 square millimeters

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description
002	.2 mitoses per 10 high-power fields (40x field) .2 mitoses per 2 square millimeters
003	.3 mitoses per 10 high-power fields (40x field) .3 mitoses per 2 square millimeters
004	.4 mitoses per 10 high-power fields (40x field) .4 mitoses per 2 square millimeters
005	.5 mitoses per 10 high-power fields (40x field) .5 mitoses per 2 square millimeters
006	.6 mitoses per 10 high-power fields (40x field) .6 mitoses per 2 square millimeters
007	.7 mitoses per 10 high-power fields (40x field) .7 mitoses per 2 square millimeters
008	.8 mitoses per 10 high-power fields (40x field) .8 mitoses per 2 square millimeters
009	.9 mitoses per 10 high-power fields (40x field) .9 mitoses per 2 square millimeters Stated as less than 1 mitoses per 10 high-power fields (40x field) Stated as less than 1 mitoses per 2 square millimeters
010-100	1-10 mitoses per 10 high-power fields (40x field) 1-10 mitoses per 2 square millimeters
110	11 or more mitoses per 10 high-power fields (40x field) 11 or more mitoses per 2 square millimeters
888	OBSOLETE DATA CONVERTED V0200 See code 988: Not applicable for this site
988	Not applicable: Information not collected for this case (May include cases converted from code 888 used in CSV1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.)
990	Specific number not stated, described less than or equal to 4 mitoses per 10 high-power fields (40x field) Specific number not stated, described less than or equal to 4 mitoses per square millimeter
995	Specific number not stated, described as greater than 4 mitoses per 10 high-power fields (40x field) Specific number not stated, described as greater than 4 mitoses per square millimeters
999	Unknown Not stated Not documented in patient record

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Pancreas: Other and Unspecified

CS Site-Specific Factor 4 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

Pancreas: Other and Unspecified

CS Site-Specific Factor 5 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

Pancreas: Other and Unspecified

CS Site-Specific Factor 6 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

Pancreas: Other and Unspecified

CS Site-Specific Factor 7 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Pancreas: Other and Unspecified

CS Site-Specific Factor 8 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Pancreas: Other and Unspecified

CS Site-Specific Factor 9 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Pancreas: Other and Unspecified

CS Site-Specific Factor 10 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Pancreas: Other and Unspecified

CS Site-Specific Factor 11 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Pancreas: Other and Unspecified

CS Site-Specific Factor 12 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Pancreas: Other and Unspecified

CS Site-Specific Factor 13 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Pancreas: Other and Unspecified

CS Site-Specific Factor 14 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Pancreas: Other and Unspecified

CS Site-Specific Factor 15 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Pancreas: Other and Unspecified

CS Site-Specific Factor 16 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Pancreas: Other and Unspecified

CS Site-Specific Factor 17 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Pancreas: Other and Unspecified

CS Site-Specific Factor 18 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Pancreas: Other and Unspecified

CS Site-Specific Factor 19 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Pancreas: Other and Unspecified

CS Site-Specific Factor 20 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Pancreas: Other and Unspecified

CS Site-Specific Factor 21 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Pancreas: Other and Unspecified

CS Site-Specific Factor 22 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Pancreas: Other and Unspecified

CS Site-Specific Factor 23 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Pancreas: Other and Unspecified

CS Site-Specific Factor 24 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Pancreas: Other and Unspecified

CS Site-Specific Factor 25 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Other and Ill-Defined Digestive Organs

C26.0, C26.8-C26.9

C26.0 Intestinal tract, NOS

C26.8 Overlapping lesion of digestive system

C26.9 Gastrointestinal tract, NOS

Note: AJCC does not define TNM staging for this site.

CS Tumor Size	CS Site-Specific Factor 1	<p>The following tables are available at the collaborative staging website: Histology Inclusion Table AJCC 7th ed. Histology Exclusion Table AJCC 6th ed. AJCC TNM 7 Stage AJCC TNM 6 Stage Summary Stage</p>
CS Extension	CS Site-Specific Factor 2	
CS Tumor Size/Ext Eval	CS Site-Specific Factor 3	
CS Lymph Nodes	CS Site-Specific Factor 4	
CS Lymph Nodes Eval	CS Site-Specific Factor 5	
Reg LN Pos	CS Site-Specific Factor 6	
Reg LN Exam	CS Site-Specific Factor 7	
CS Mets at DX	CS Site-Specific Factor 8	
CS Mets Eval	CS Site-Specific Factor 9	
	CS Site-Specific Factor 10	
	CS Site-Specific Factor 11	
	CS Site-Specific Factor 12	
	CS Site-Specific Factor 13	
	CS Site-Specific Factor 14	
	CS Site-Specific Factor 15	
	CS Site-Specific Factor 16	
	CS Site-Specific Factor 17	
	CS Site-Specific Factor 18	
	CS Site-Specific Factor 19	
	CS Site-Specific Factor 20	
	CS Site-Specific Factor 21	
	CS Site-Specific Factor 22	
	CS Site-Specific Factor 23	
	CS Site-Specific Factor 24	
	CS Site-Specific Factor 25	

Other and Ill-Defined Digestive Organs

CS Tumor Size (Revised: 02/03/2010)

Code	Description
000	No mass/tumor found
001-988	001 - 988 millimeters (code exact size in millimeters)
989	989 millimeters or larger
990	Microscopic focus or foci only and no size of focus given
991	Described as "less than 1 cm"
992	Described as "less than 2 cm," or "greater than 1 cm," or "between 1 cm and 2 cm"
993	Described as "less than 3 cm," or "greater than 2 cm," or "between 2 cm and 3 cm"
994	Described as "less than 4 cm," or "greater than 3 cm," or "between 3 cm and 4 cm"
995	Described as "less than 5 cm," or "greater than 4 cm," or "between 4 cm and 5 cm"

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description
999	Unknown; size not stated Not documented in patient record

Other and Ill-Defined Digestive Organs

CS Extension (Revised: 07/06/2009)

Note 1: Definition of Adjacent Connective Tissue: Some of the schemes for ill-defined or non-specific sites in this manual contain a code 40, adjacent connective tissue, which is defined here as the unnamed tissues that immediately surround an organ or structure containing a primary cancer. Use this code when a tumor has invaded past the outer border (capsule, serosa, or other edge) of the primary organ into the organ's surrounding supportive structures but has not invaded into larger structures or adjacent organs.

Note 2: Definition of Adjacent Structures: Connective tissues large enough to be given a specific name would be considered adjacent structures. For example, the brachial artery has a name, as does the broad ligament. Continuous tumor growth from one organ into an adjacent named structure would be coded to 60 in the schemes for ill-defined or non-specific sites.

Code	Description	TNM 7	TNM 6	SS77	SS2000
000	In situ; non-invasive; intraepithelial	NA	NA	IS	IS
100	Invasion of submucosa	NA	NA	L	L
300	Localized, NOS	NA	NA	L	L
400	Adjacent connective tissue (see Note 1)	NA	NA	RE	RE
600	Adjacent organs/structures (see Note 2)	NA	NA	RE	RE
800	Further contiguous extension	NA	NA	D	D
950	No evidence of primary tumor	NA	NA	U	U
999	Unknown extension Primary tumor cannot be assessed Not documented in patient record	NA	NA	U	U

Other and Ill-Defined Digestive Organs

CS Tumor Size/Ext Eval (Revised: 11/03/2009)

Note: The staging basis for this schema is blank because AJCC stage is not applicable.

Code	Description	Staging Basis
9	Not applicable for this schema	

Other and Ill-Defined Digestive Organs

CS Lymph Nodes (Revised: 06/30/2008)

Note: Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in the field Mets at DX.

Code	Description	TNM 7	TNM 6	SS77	SS2000
000	None; no regional lymph node involvement	NA	NA	NONE	NONE

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description	TNM 7	TNM 6	SS77	SS2000
100	Regional lymph nodes Intra-abdominal Paracaval Pelvic Subdiaphragmatic Regional lymph nodes, NOS	NA	NA	RN	RN
800	Lymph nodes, NOS	NA	NA	RN	RN
999	Unknown; not stated Regional lymph nodes cannot be assessed Not documented in patient record	NA	NA	U	U

Other and Ill-Defined Digestive Organs

CS Lymph Nodes Eval (Revised: 11/03/2009)

Note: The staging basis for this schema is blank because AJCC stage is not applicable.

Code	Description	Staging Basis
9	Not applicable for this schema	

Other and Ill-Defined Digestive Organs

Reg LN Pos (Revised: 03/30/2009)

Note: Record this field even if there has been preoperative treatment.

Code	Description
00	All nodes examined negative.
01-89	1 - 89 nodes positive (code exact number of nodes positive)
90	90 or more nodes positive
95	Positive aspiration or core biopsy of lymph node(s)
97	Positive nodes - number unspecified
98	No nodes examined
99	Unknown if nodes are positive; not applicable Not documented in patient record

Other and Ill-Defined Digestive Organs

Reg LN Exam (Revised: 03/02/2009)

Code	Description
00	No nodes examined
01-89	1 - 89 nodes examined (code exact number of regional lymph nodes examined)
90	90 or more nodes examined

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description
95	No regional nodes removed, but aspiration or core biopsy of regional nodes performed
96	Regional lymph node removal documented as sampling and number of nodes unknown/not stated
97	Regional lymph node removal documented as dissection and number of nodes unknown/not stated
98	Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection; nodes examined, but number unknown
99	Unknown if nodes were examined; not applicable or negative Not documented in patient record

Other and Ill-Defined Digestive Organs

CS Mets at DX (Revised: 11/19/2009)

Code	Description	TNM 7	TNM 6	SS77	SS2000
00	No; none	NA	NA	NONE	NONE
10	Distant lymph node(s), NOS	NA	NA	D	D
40	Distant metastases except distant lymph node(s) (code 10) Carcinomatosis	NA	NA	D	D
50	40 + 10 Other distant metastases plus distant lymph node(s)	NA	NA	D	D
60	Distant metastasis, NOS	NA	NA	D	D
99	Unknown if distant metastasis Distant metastasis cannot be assessed Not documented in patient record	NA	NA	U	U

Other and Ill-Defined Digestive Organs

CS Mets Eval (Revised: 11/03/2009)

Note: The staging basis for this schema is blank because AJCC stage is not applicable.

Code	Description	Staging Basis
9	Not applicable for this schema	

Other and Ill-Defined Digestive Organs

CS Site-Specific Factor 1 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Digestive Organs

CS Site-Specific Factor 2 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

Other and Ill-Defined Digestive Organs

CS Site-Specific Factor 3 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

Other and Ill-Defined Digestive Organs

CS Site-Specific Factor 4 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

Other and Ill-Defined Digestive Organs

CS Site-Specific Factor 5 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Other and Ill-Defined Digestive Organs

CS Site-Specific Factor 6 (Revised: 06/30/2008)

Code	Description
888	OBSOLETE DATA CONVERTED V0200 See code 988 Not applicable for this site
988	Not applicable for this schema

Other and Ill-Defined Digestive Organs

CS Site-Specific Factor 7 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Digestive Organs

CS Site-Specific Factor 8 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Digestive Organs

CS Site-Specific Factor 9 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Digestive Organs

CS Site-Specific Factor 10 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Digestive Organs

CS Site-Specific Factor 11 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Other and Ill-Defined Digestive Organs

CS Site-Specific Factor 12 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Digestive Organs

CS Site-Specific Factor 13 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Digestive Organs

CS Site-Specific Factor 14 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Digestive Organs

CS Site-Specific Factor 15 (Revised: 06/30/2008)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Digestive Organs

CS Site-Specific Factor 16 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Digestive Organs

CS Site-Specific Factor 17 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Digestive Organs

CS Site-Specific Factor 18 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

**Collaborative Stage Data Collection System Coding Instructions
PART II: Site-Specific Schemas**

The official version of this document is online at www.cancerstaging.org/cstage/manuals.

Other and Ill-Defined Digestive Organs

CS Site-Specific Factor 19 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Digestive Organs

CS Site-Specific Factor 20 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Digestive Organs

CS Site-Specific Factor 21 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Digestive Organs

CS Site-Specific Factor 22 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Digestive Organs

CS Site-Specific Factor 23 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Digestive Organs

CS Site-Specific Factor 24 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema

Other and Ill-Defined Digestive Organs

CS Site-Specific Factor 25 (Revised: 02/23/2009)

Code	Description
988	Not applicable for this schema